ALFRED K CHEUNG portrait
  • Adjunct Professor, Pharmaceutical Chemistry
  • Professor, Internal Medicine
801-585-5215

Presentations

  • “Adequacy of hemodialysis: time and volume are essences”, Blood Purification Forum, Chinese Society of Nephrology, Xiamen. , , 2016.
  • “Blood pressure target for treatment of hypertension”, 18th South China International Congress of Cardiology, Guangzhou, China. , , 2016.
  • “Blood pressure target in chronic kidney disease”, 2016 Translational Medicine Forum, Nanfang Hospital,. , , 2016.
  • “Biological obstacles for fistula maturation”, Am Soc Artificial Internal Organs Annual Meeting, Chicago. , , 2015.
  • “Current hemodialysis arteriovenous access research”, UU-TVGH-NYMU-NCTU Forum on Hemodialysis Vascular Access Research, Taipei. , , 2015.
  • “Past and present of uremic cardiomyopathy”, American Society of Nephrology Renal Week. , , 2015.
  • . “Clinical outcomes of maintenance hemodiafiltration and other dialytic therapies”, 16th Annual Southwest Nephrology Conference, Scottsdale. , , 2015.
  • “The vulnerable patient with CKD: a new concept of blood changes in uremia”, World Congress of Nephrology, Cape Town, South Africa. , , 2015.
  • “Volume management in chronic hemodialysis”, 16th Annual Southwest Nephrology Conference, Scottsdale. , , 2015.
  • . “Management of common medical problems in dialysis patients”, American Society of Nephrology Board Review Course Update, Chicago. , , 2015.
  • “Selected complications on hemodialysis: a case-based approach”, American Society of Nephrology Board Review Course Update, Chicago. , , 2015.
  • Second Xiangya Hospital of Central South University, China. , , 2015.
  • “Trial types – Where does cluster randomization fit in?”, American Society of Nephrology Annual Meeting (Kidney Week). , , 2014.
  • “Volume management in chronic hemodialysis”, DSI Medical Director Annual Meeting, Miami Beach. , , 2014.
  • “Highlights of NKF Spring Clinical Meeting”, National Kidney Foundation China Meeting, webcast from Salt Lake City. , , 2014.
  • University of Virginia. , , 2013.
  • “Hypertension control and CKD progression”, World Congress of Nephrology Satellite Symposium on Renal Fibrosis, Guangzhou, China. , , 2013.
  • “Selecting blood pressure targets for older adults with CKD”, American Society of Nephrology Annual Meeting (Kidney Week). , , 2013.
  • University of Alabama. , , 2013.
  • “Hypertension control and CKD progression”, Ningbo Society of Nephrology, Ningbo, China. , , 2013.
  • “Hemodiafiltration: Another failed strategy or true breakthrough?”, American Society of Nephrology Annual Meeting (Kidney Week). , , 2012.
  • . “Hemodialysis vascular access: Minimizing catheter use and maximizing long-term success”, American Society of Nephrology Annual Meeting (Kidney Week). , , 2012.
  • “Explanatory and pragmatic trials”, Arbor Research. , , 2012.
  • “Morbidity and mortality in dialysis patients”, Mexican National Association of Nephrologists 5th Annual Meeting, Guanajuato. , , 2012.
  • “Mineral bone disorder in dialysis patients”, Mexican National Association of Nephrologists 5th Annual Meeting, Guanajuato. , , 2012.
  • “Justification for Chronic Kidney Disease Subgroup in SPRINT”, American Society of Hypertension Annual Meeting, New York City. , , 2012.
  • “Are physicians the main barrier for greater use of home dialysis?”, National Kidney Foundation Spring Clinical Meeting, Baltimore. , , 2012.
  • University of Colorado (Collins Visiting Professorship). , , 2011.
  • University of Texas Southwestern. , , 2009.
  • Henry Ford Hospital. , , 2008.
  • Tufts/New England Medical Center. , , 2006.
  • Harvard University. , , 2006.
  • Stanford University. , , 2006.
  • Medical University of Ohio. , , 2005.
  • University of Pittsburgh. , , 2004.
  • Case Western Reserve University. , , 2004.
  • University of Florida (GCRC Visiting Scientist), Gainesville. , , 1999.
  • Duke University. , , 1999.
  • University of Iowa. , , 1998.
  • Tufts University. , , 1996.
  • Hunan Medical University, China. , , 1996.
  • University of Florida, Gainesville. , , 1996.
  • University of California, Los Angeles. , , 1995.
  • Indiana University. , , 1995.
  • University of California, San Diego. , , 1994.
  • Henry Ford Hospital. , , 1993.
  • University of Louisville. , , 1993.
  • “Trial types: where do pragmatic trials fit in?”, Pragmatic Trials in AKI and RRT Roundtable, San Diego. , , 2016.
  • “Justification for Chronic Kidney Disease Subgroup in SPRINT”, American Society of Hypertension Annual Meeting, New York City. , , 2012.
  • “Are physicians the main barrier for greater use of home dialysis?”, National Kidney Foundation Spring Clinical Meeting, Baltimore. , , 2012.
  • “Cardiovascular protection in CKD and dialysis”, 13th Annual Southwest Nephrology Conference, Scottsdale. , , 2012.
  • “Morbidity and mortality in dialysis patients”, 13th Annual Southwest Nephrology Conference, Scottsdale. , , 2012.
  • “SPRINT: High risk CKD subgroup within a larger clinical trial”, Conference on “Reducing the Impact of Chronic Kidney Disease: Opportunities from Randomized Clinical Trials”, NIDDK. , , 2011.
  • “Women and dialysis”, 12th Annual Southwest Nephrology Conference, Scottsdale. , , 2011.
  • “Initiation of chronic dialysis”, 12th Annual Southwest Nephrology Conference, Scottsdale. , , 2011.
  • “Biology of arteriovenous access stenosis and targets for therapy”, New York Society of Nephrology Annual Meeting. , , 2011.
  • “Dry Weight Assessment and Fluid Management”, Renal Advantage Inc. Annual Conference, Scottsdale. , , 2011.
  • “Hemodialysis solute transport and assessment of adequacy”, American Society of Nephrology Annual Meeting. , , 2011.
  • “Lesson learned from controlled trials in nephrology”, American Society of Nephrology Annual Meeting,. , , 2011.
  • “Data safety monitoring and steering committees”, American Society of Nephrology Annual Meeting. , , 2011.
  • “Uncertainties in blood pressure target in chronic kidney disease”, Guangdong Society of Nephrology Annual Meeting, Jiangmen, China. , , 2011.
  • “Problems with nephrology clinical trials”, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. , , 2011.
  • “Hypothesis-driven clinical research in dialysis”, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. , , 2011.
  • “Key elements in multicenter randomized trials”, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. , , 2011.
  • “ESRD”, American Society of Nephrology Renal Weekends, Berlin. , , 2010.
  • “ESRD”, American Society of Nephrology Renal Weekends, Dallas. , , 2010.
  • “Report on Controversies Conference: Blood pressure in dialysis patients”, National Kidney foundation Annual Spring Meeting, Orlando. , , 2010.
  • “ESRD”, American Society of Nephrology Renal Weekends, Los Angeles. , , 2010.
  • “Impact of vascular access on morbidity and mortality”, Renal Advantage Inc. Annual Conference, San Diego. , , 2010.
  • “Areas for improvement: Insights from past randomized trials”, American Society of Nephrology Annual Meeting. , , 2010.
  • “What is the evidence of blood pressure lowering, optimal targets, and agents in CKD?”, American Society of Nephrology Annual Meeting. , , 2010.
  • “ESRD”, American Society of Nephrology Renal Weekends, San Francisco. , , 2009.
  • “Vascular access failure: basic science”, American Society of Nephrology Annual Meeting. , , 2009.
  • “Cardiovascular disease in dialysis patients”, American Renal Associates, Miami. , , 2009.
  • “Pathobiology of vascular access failure”, National Kidney Foundation serving Georgia, Hilton Head Island. , , 2009.
  • “Dialyzer size and adequacy: Is bigger always better?”, Renal Advantage Inc. Annual Conference, Bonita Springs. , , 2009.
  • “Lipid control: Is it really needed in the ESRD patient?”, ESRD: State of the Art and Charting the Challenges for the Future, Continuing Education Conference, Harvard Medical School. , , 2009.
  • “ESRD”, American Society of Nephrology Renal Weekends, Mexico City. , , 2009.
  • “ESRD”, American Society of Nephrology Renal Weekends, Chicago. , , 2009.
  • “Inhibition of cellular proliferation in vascular accesses: new approaches”, Advances in CKD 2009, 11th International Conference on Dialysis, Renal Research Institute, Las Vegas. , , 2009.
  • “ESRD”, American Society of Nephrology Renal Weekends, Berlin. , , 2009.
  • “Cardiovascular risks in chronic kidney disease” 9th Annual Southwest Nephrology Conference, Phoenix. , , 2008.
  • “Local drug therapy for prevention of vascular access stenosis”, 28th Annual Dialysis Conference, Orlando. , , 2008.
  • “Solute clearance in hemodialysis”, Hong Kong Society of Nephrology, Hong Kong. , , 2008.
  • “ESRD”, American Society of Nephrology Renal Weekends, Los Angeles. , , 2008.
  • “Hemodialysis vascular access”, Hong Kong University, Hong Kong. , , 2008.
  • “Prescribing Cardiovascular Medications in Dialysis Patients”, National Kidney Foundation Annual Scientific Meeting, Dallas. , , 2008.
  • “Cardiovascular disease in chronic kidney disease”, Medicine grand rounds, Henry Ford Hospital. , , 2008.
  • “Dialyzer membranes: Structure, function and patient reactions”, Renal Advantage Inc. Annual Conference, Scottsdale. , , 2008.
  • “End-of-life issues on dialysis”, Easterling Dinner Lecture, National Kidney Foundation of Michigan. , , 2008.
  • “Debate: Hemodialysis vs. peritoneal dialysis”, Hong Kong Society of Nephrology, Hong Kong. , , 2008.
  • “Native arteriovenous fistula maturation”, Kidney Epidemiology and Cost Center, University of Michigan. , , 2008.
  • “Is CVD in CKD different from non-CKD”, Renal Advantage Inc. Annual Conference, Scottsdale. , , 2008.
  • “Hemodialysis vascular access”, Combined Nephrology Conference, University of Michigan. , , 2008.
  • “Prevention of vascular access stenosis”, University of California, Davis. , , 2007.
  • “Local drug delivery for prevention of vascular access stenosis”, 5th International Congress of Uremic Research and Toxicity and 7th Baltic Meeting on Nephrology, Gdansk and Sopot, Poland. , , 2007.
  • “Nutrition and inflammation in dialysis patients” 8th Annual Southwest Nephrology Conference, Phoenix. , , 2007.
  • “Home hemodialysis” 8th Annual Southwest Nephrology Conference, Phoenix. , , 2007.
  • “Evidence-based HD: Did we learn any more from this HEMO study than the last one?”, Berlin Dialysis Seminar, Berlin. , , 2007.
  • “New directions in maintaining vascular access patency”, Nephrology for the Consultant conference, University of California, San Diego. , , 2006.
  • “Comparative outcomes of HD and PD”, National Kidney Foundation Annual Scientific Meeting, Chicago. , , 2006.
  • “Treatments for CVD in CKD”, National Kidney Foundation Annual Scientific Meeting, Chicago. , , 2006.
  • “Is CVD management in advanced CKD different from the general population?”, Dialysis Clinic Inc., Reno. , , 2006.
  • “New directions in maintaining vascular access patency”, Renal Advantage Inc. Annual Conference, Scottsdale. , , 2006.
  • “The epidemic of cardiovascular disease in CKD”, National Kidney Foundation of Tennessee, Memphis. , , 2006.
  • “K/DOQI Guidelines and cardiovascular management of ESRD”, Southern California Kaiser Permanente Nephrology Symposium. , , 2005.
  • “Three years after HEMO: what has changed and what should change”, Nephrology for the Consultant conference, University of California, San Diego. , , 2005.
  • “Clinical trials in dialysis: An appraisal of results and ongoing trials”, American Society of Nephrology Annual Meeting. , , 2005.
  • “Rethinking the prescription of chronic HD”, American Society of Nephrology Annual Meeting. , , 2005.
  • “Progress and challenges in local delivery of therapeutic agents”, American Society of Nephrology Annual Meeting. , , 2005.
  • “Integrative ESRD Care”, Korean Society of Nephrology Meeting. , , 2005.
  • “Coronary artery disease in ESRD”, Southern California Kaiser Permanente Nephrology Symposium. , , 2005.
  • “K/DOQI Guidelines on Cardiovascular Disease in Dialysis Patients”, European Renal Association/European Dialysis & Transplant Association. , , 2005.
  • “Coronary artery disease in dialysis patients”, Korean Society of Nephrology Meeting. , , 2005.
  • “What do we know about cardiovascular disease in dialysis patients?”, International Symposium, Yonsei University Kidney Center, Korea. , , 2005.
  • “Current management of chronic kidney disease”, National Kidney Foundation of Utah. , , 2005.
  • “Chronic hemodialysis prescriptions in the post-HEMO Study era”, International Symposium, Yonsei University Kidney Center, Korea. , , 2005.
  • "Comparative outcomes of hemodialysis vs. peritoneal dialysis", National Kidney Foundation Annual Scientific Meeting. , , 2005.
  • "K/DOQI guidelines on cardiovascular disease in dialysis patients", National Kidney Foundation of Singapore. , , 2004.
  • "New clinical trials in dialysis: An appraisal of results and ongoing trials", American Society of Nephrology Annual Meeting. , , 2004.
  • "Secondary analyses of HEMO Study", National Kidney Foundation Annual Scientific Meeting. , , 2004.
  • "Cardiovascular disease in chronic kidney disease", Univ. of California, Irvine. , , 2004.
  • Vanderbilt University. , , 2004.
  • "Implications of the HEMO Study for future chronic therapy", World Congress of Nephrology evening symposium. , , 2003.
  • "Cardiovascular disease in chronic kidney disease", Symposium on "Improving Outcomes in CKD and ESRD Patients", sponsored by Amgen, Scottsdale, AZ. , , 2003.
  • "Overview and hypertension in chronic kidney disease" and "Initiation of chronic dialysis", Southern California Kaiser Permanente Nephrology Symposium. , , 2003.
  • "Design and results of the HEMO Study", New York Society of Nephrology. , , 2003.
  • "Cardiovascular disease in chronic kidney disease", National Kidney Foundation of Tennessee and University of Tennessee, Memphis, TN. , , 2003.
  • "Lessons from the HEMO and the ADEMEX Study", National Kidney Foundation Annual Scientific Meeting. , , 2003.
  • "Summary of HEMO Study", American Society for Artificial Internal Organs. , , 2003.
  • "High efficiency and high flux dialyzers", Dimensions in Dialysis Conference, Legacy Health System. , , 2002.
  • "Primary outcomes of HEMO Study", American Society of Nephrology Annual Meeting. , , 2002.
  • "HEMO trial secondary analyses", American Society for Artificial Internal Organs. , , 2002.
  • "Basics of hemodialysis membrane biocompatibility", 8th International Symposium on Hemodialysis. , , 2002.
  • "Hemodialysis membranes", National Kidney Foundation Annual Scientific Meeting. , , 2002.
  • "On-line monitoring during hemodialysis", National Kidney Foundation Annual Scientific Meeting. , , 2002.
  • "Additional analysis of flux intervention in HEMO Study", American Society of Nephrology Annual Meeting. , , 2002.
  • "Uremic toxicity of low-molecular weight proteins", 8th International Symposium on Hemodialysis. , , 2002.
  • "Treatment of hypertension in Pre-ESRD and ESRD", 2001 Nephrology Symposium, Southern California Permanente Medical Group. , , 2001.
  • "Blood volume monitoring: a critical appraisal", American Society of Nephrology Annual Meeting. , , 2001.
  • Hypertension in chronic renal failure , Southern California Kaiser Permanente Nephrology Symposium. , , 2001.
  • "Hemodialysis prescription and adequacy," "Membranes and anticoagulation for continuous renal replacement therapy," and "Debate Kt/V: The best measure of hemodialysis adequacy?" Nephroasia/ASN/ANNA Symposium. , , 2001.
  • "Membranes for hemodialysis", National Kidney Foundation Annual Scientific Meeting. , , 2001.
  • "Basics of biocompatibility", 7th International Symposium on Hemodialysis. , , 2001.
  • "Uremic middle molecules" PLIVA symposium, Zagreb, Croatia. , , 2000.
  • "Dry weight, blood volume and intradialytic symptoms", Postgraduate Education Course, American Society of Nephrology Annual Meeting. , , 2000.
  • "On-line hematocrit and urea monitoring", American Society of Nephrology Annual Meeting. , , 2000.
  • "Uremic middle molecules" & "Current status of hemodialysis membrane biocompatibility", University of Guadalajara, Mexico. , , 1999.
  • "Hemodialysis biocompatibility", Colloq on Biocompatibility, Univ of Louisville. , , 1999.
  • "Vascular access monitoring", Univ. of Guadalajara, Mexico. , , 1998.
  • Nephrology Update, Kidney Dialysis Foundation, Singapore. , , 1997.
  • "Dialyzer function and reuse" Am Soc of Nephrology Ann Mtg. , , 1997.
  • "Volume assessment: is there anything new?" Am Soc of Nephrol Ann Mtg. , , 1995.
  • "Biocompatibility of artificial membranes: an overview" National Kidney Foundation Annual Scientific Meeting. , , 1995.
  • "On line measurement of blood volume and its clinical significance" National Kidney Foundation Annual Scientific Meeting. , , 1994.
  • Panel discussant, "Effects of reprocessing techniques on dialyzer function: assessment and analysis" Association for Advancement of Medical Instrumentation meeting, Washington DC. , , 1994.
  • "Quantitation of dialysis", Renal Physician Assoc & NIDDK Joint Annual Meeting, San Diego. , , 1993.
  • Lipid abnormalities in ESRD" & "Hemodialysis Membrane biocompatibility: What is the significance?" Harvard Medical School Postgrad CME Course, Boston. , , 1993.
  • "Technical aspects of hemodialysis in the United States", Asian Conference "Trends in Dialysis", National Medical Care, Shanghai, People's republic of China. , , 1993.
  • "Hemodialysis membrane biocompatibility", Hong Kong Society of Nephrology,Hong Kong. , , 1993.
  • Clinical phenomena induced by complement and leukocyte interactions with artificial surfaces, Am Society for Apheresis XIIIth Annual Meeting, Chicago. , , 1992.
  • "Biocompatibility of dialysis membranes" National Kidney Foundation of North Carolina Annual Meeting, Wilmington, NC. , , 1992.
  • Mechanisms and consequences of Symposium, Greenfield Health System, Toledo, OH. , , 1991.
  • High efficiency dialysis and adequacy of hemodialysis" & "Biocompatibility of hemodialysis membranes", Xth Ann Course in Clin Nephrology, Mexico City. , , 1990.
  • Mechanisms of complement activation on hemodialysis membranes" Am Soc Artificial Internal Organs Annual Meeting, Washington DC. , , 1990.
  • "Dialysis membrane biocompatibility", Am Soc of Nephrology Ann Mtg. , , 1989.
  • Clinical aspects of hemodialysis biocompatibility, "Current Therapy in Nephrology", Sorrento, Italy. , , 1988.
  • Advances in artificial kidney treatment" & "Biocompatibility of artificial kidney membranes", 7th Asian Colloquium in Nephrology, Taipei, Taiwan. , , 1987.
  • Biocompatibility of dialysis membranes: potential clinical and immunological effects" Renal Physicians Association Annual Meeting. , , 1986.
  • Dialysis membrane biocompatibility, International Symposium, Immune and Metabolic Aspects of Blood Purification Systems, Trondheim, Norway. , , 1985.

Languages

  • English, Fluent.
  • Cantonese, Fluent.

Publications

  • Leypoldt JK, Henderson LW, Cheung AK (date unknown). Middle molecules. World Scientific Publishing. Accepted, .
  • Leypoldt JK, Culleton BF, Cheung AK (date unknown). Hemodialysis adequacy. (pp. 320-334). Elsevier. Accepted, .
  • Cheung, AK (date unknown). Hemodialysis and hemofiltration. (pp. 446-458). Saunders Elsevier. Accepted, .
  • Reddy B, Cheung AKH (date unknown). Hemodialysis. (pp. 201-223). Imperial College Press and World Scientific Publisher. Accepted, .
  • Ford L, Ward RA, Cheung AK (date unknown). Choice of the hemodialysis membrane. (pp. 1-11). Lippincott Williams & Wilkins. Accepted, .
  • Wali R, Kaluvapalle JR, Cheung AK (date unknown). Complications associated with hemodialysis. (pp. 891-912). Elsevier Saunders. Accepted, .
  • Cheung AK (date unknown). Hemodialysis and hemofiltration. (pp. 464-476). Elsevier. Accepted, .
  • Cheung AK (date unknown). Hemodialysis and hemofiltration. In: National Kidney Foundation Primer on Kidney Diseases. (pp. 396-404). Academic Press. Accepted, .
  • Greene T, Cheung AK, Krediet R (date unknown). : The design of randomized clinical trials in dialysis patients. (pp. 1521-1542). Kluwer Academic Press. Accepted, .
  • Pereira BG, Cheung AK (date unknown). Biocompatibility of hemodialysis membrane. (pp. 32-56). WB Saunders. Accepted, .
  • Pereira BJG, Cheung AK (date unknown). Complications of biocompatibility of hemodialysis membranes. (pp. 41-68). Marcel Dekker. Accepted, .
  • Ambalavanan S, Rabetoy G, Cheung A (date unknown). High efficiency and high flux hemodialysis. (pp. 1-3.10). Vol. 3. Accepted, .
  • Leypoldt JK, Cheung AK: Fluid removal during hemodialysis (date unknown). Fluid removal during hemodialysis. (pp. 1-23). Accepted, .
  • Cheung AK (date unknown). Hemodialysis and hemofiltration. (pp. 408-415). Academic Press. Accepted, .
  • Leypoldt JK, Cheung AK (date unknown). Dialyzer reprocessing and solute clearances. (pp. 333-339). Vol. 3. Accepted, .
  • Walton DF, Cheung AK (date unknown). Membrane biocompatibility. (pp. 1029-1042). Kluwer Academic Publishers. Accepted, .
  • Cheung AK, Mohammad SF, Leypoldt JK (date unknown). Adhesion molecules and artificial membranes. (pp. 643-678). Accepted, .
  • Walton DF, Cheung AK (date unknown). Membrane biocompatibility. Appleton & Lange. Accepted, .
  • Cheung AK (date unknown). Hemodialysis and hemofiltration. (pp. 258-265). Academic Press. Accepted, .
  • Cheung AK (date unknown). Dialyzer biocompatibility: Practical considerations. (pp. 75-77). Hanley & Belfus, Inc. Accepted, .
  • Loghman-Adham M, Walton D, Iverius PH, Deiss A, Knight JA, Cheung AK (date unknown). Spurious hypophosphatemia in a patient with multiple myeloma. (pp. 571-5). Vol. 30. Accepted, .
  • Beckwith C, Flaharty KK, Cheung AK, Beatty PG (date unknown). Fanconi's syndrome due to ifosfamide. (pp. 71-3). Vol. 11. Accepted, .
  • Chang TI, Cheung AK, Chertow GM (date unknown). Blood pressure control in type 2 diabetes mellitus. Vol. 56, 1029-31. Accepted, .
  • Cheung AK, Greene T (date unknown). Effect of membrane permeability on survival of hemodialysis patients. Vol. 20, 462-4. Accepted, .
  • Henderson LW, Leypoldt JK, Lysaght MJ, Cheung AK (date unknown). Death on dialysis and the time/flux trade-off. Vol. 15, 1-14. Accepted, .
  • Cheung AK (date unknown). Biocompatibility of Dialysis membrane: Practical considerations. 139-149. Accepted, .
  • Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R (date unknown). Effect of dialysis dose and membrane flux in maintenance hemodialysis. Vol. 347, 2010-9. Accepted, .
  • Li L, Blumenthal DK, Masaki T, Terry CM, Cheung AK (date unknown). Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. Vol. 99, 1553-63. Accepted, .
  • Zhuplatov SB, Masaki T, Blumenthal DK, Cheung AK (date unknown). Mechanism of dipyridamole's action in inhibition of venous and arterial smooth muscle cell proliferation. Vol. 99, 431-9. Accepted, .
  • Thekkedath UR, Chirananthavat T, Leypoldt JK, Cheung AK, Mohammad SF (date unknown). Elevated fibrinogen fragment levels in uremic plasma inhibit platelet function and expression of glycoprotein IIb-IIIa. Vol. 81, 915-26. Accepted, .
  • Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G (date unknown). Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. Vol. 14, 3251-63. Accepted, .
  • Goldfarb-Rumyantzev AS, Cheung AK, Leypoldt JK (date unknown). Computer simulation of small-solute and middle-molecule removal during short daily and long thrice-weekly hemodialysis. Vol. 40, 1211-8. Accepted, .
  • Leypoldt JK, Charney DI, Cheung AK, Naprestek CL, Akin BH, Shockley TR (date unknown). Ultrafiltration and solute kinetics using low sodium peritoneal dialysate. Vol. 48, 1959-66. Accepted, .
  • Cheung AK, Parker CJ, Hohnholt M (date unknown). Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Vol. 46, 1680-7. Accepted, .
  • Beddhu S, Ma X, Baird B, Cheung AK, Greene T (date unknown). Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. Vol. 4, 1805-10. Accepted, .
  • Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, El Nahas M, Feldt-Rasmussen B, Lange M, Mitch WE, Wanner C, Wiedemann J, Ikizler TA (date unknown). OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients. Vol. 3, 1741-51. Accepted, .
  • Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK (date unknown). The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Vol. 50, 791-802. Accepted, .
  • Beddhu S, Cheung AK, Larive B, Greene T, Kaysen GA, Levey AS, Rocco M, Sarnak M, Toto R, Eknoyan G (date unknown). Inflammation and inverse associations of body mass index and serum creatinine with mortality in hemodialysis patients. Vol. 17, 372-80. Accepted, .
  • Li L, Terry CM, Blumenthal DK, Kuji T, Masaki T, Kwan BC, Zhuplatov I, Leypoldt JK, Cheung AK (date unknown). Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. Vol. 22, 3139-46. Accepted, .
  • Terry CM, Blumenthal DK, Sikharam S, Li L, Kuji T, Kern SE, Cheung AK (date unknown). Evaluation of histological techniques for quantifying haemodialysis arteriovenous (AV) graft hyperplasia. Vol. 21, 3172-9. Accepted, .
  • Masaki T, Rathi R, Zentner G, Leypoldt JK, Mohammad SF, Burns GL, Li L, Zhuplatov S, Chirananthavat T, Kim SJ, Kern S, Holman J, Kim SW, Cheung AK (date unknown). Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. Vol. 66, 2061-9. Accepted, .
  • Beddhu S, Allen-Brady K, Cheung AK, Horne BD, Bair T, Muhlestein JB, Anderson JL (date unknown). Impact of renal failure on the risk of myocardial infarction and death. Vol. 62, 1776-83. Accepted, .
  • Leypoldt JK, Cheung AK, Deeter RB (date unknown). Single compartment models for evaluating beta 2-microglobulin clearance during hemodialysis. Vol. 43, 904-9. Accepted, .
  • Zhu W, Masaki T, Cheung AK, Kern SE (date unknown). Cellular pharmacokinetics and pharmacodynamics of dipyridamole in vascular smooth muscle cells. Vol. 72, 956-64. Accepted, .
  • Lee RM, Masaki T, Yang HS, Liu J, Chen J, Li L, Blumenthal DK, Cheung AK (date unknown). Different signaling responses to anti-proliferative agents in human aortic and venous smooth muscle cells. Vol. 99, 835-44. Accepted, .
  • Habib AN, Baird BC, Leypoldt JK, Cheung AK, Goldfarb-Rumyantzev AS (date unknown). The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Vol. 21, 2881-92. Accepted, .
  • Beddhu S, Kimmel PL, Ramkumar N, Cheung AK (date unknown). Associations of metabolic syndrome with inflammation in CKD: results From the Third National Health and Nutrition Examination Survey (NHANES III). Vol. 46, 577-86. Accepted, .
  • Ramkumar N, Cheung AK, Pappas LM, Roberts WL, Beddhu S (date unknown). Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. Vol. 14, 201-7. Accepted, .
  • Leypoldt JK, Cheung AK, Deeter RB, Goldfarb-Rumyantzev A, Greene T, Depner TA, Kusek J (date unknown). Kinetics of urea and beta-microglobulin during and after short hemodialysis treatments. Vol. 66, 1669-76. Accepted, .
  • Beddhu S, Kaysen GA, Yan G, Sarnak M, Agodoa L, Ornt D, Cheung AK (date unknown). Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Vol. 40, 721-7. Accepted, .
  • Leypoldt JK, Cheung AK, Deeter RB (date unknown). Rebound kinetics of beta2-microglobulin after hemodialysis. Vol. 56, 1571-7. Accepted, .
  • Moser L, Callahan KS, Cheung AK, Stoddard GJ, Munger MA (date unknown). ACE inhibitor effects on platelet function in stages I-II hypertension. Vol. 30, 461-7. Accepted, .
  • Wald R, Sarnak MJ, Tighiouart H, Cheung AK, Levey AS, Eknoyan G, Miskulin DC (date unknown). Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Vol. 52, 531-40. Accepted, .
  • Kuji T, Masaki T, Li L, Cheung AK (date unknown). Expression of C-reactive protein in myointimal hyperplasia in a porcine arteriovenous graft model. Vol. 22, 2469-75. Accepted, .
  • Kim SJ, Masaki T, Leypoldt JK, Kamerath CD, Mohammad SF, Cheung AK (date unknown). Arterial and venous smooth-muscle cells differ in their responses to antiproliferative drugs. Vol. 144, 156-62. Accepted, .
  • Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Ramkumar N, Pappas LM, Cheung AK (date unknown). Impact of timing of initiation of dialysis on mortality. Vol. 14, 2305-12. Accepted, .
  • Cheung AK, Yan G, Greene T, Daugirdas JT, Dwyer JT, Levin NW, Ornt DB, Schulman G, Eknoyan G (date unknown). Seasonal variations in clinical and laboratory variables among chronic hemodialysis patients. Vol. 13, 2345-52. Accepted, .
  • Leypoldt JK, Cheung AK (date unknown). Increases in mass transfer-area coefficients and urea Kt/V with increasing dialysate flow rate are greater for high-flux dialyzers. Vol. 38, 575-9. Accepted, .
  • Yarar D, Cheung AK, Sakiewicz P, Lindsay RM, Paganini EP, Steuer RR, Leypoldt JK (date unknown). Ultrafiltration method for measuring vascular access flow rates during hemodialysis. Vol. 56, 1129-35. Accepted, .
  • Owen SC, Li H, Sanders WG, Cheung AK, Terry CM (date unknown). Correlation of tissue drug concentrations with in vivo magnetic resonance images of polymer drug depot around arteriovenous graft. Vol. 146, 23-30. Accepted, .
  • Bress AP, King JB, Kreider KE, Beddhu S, Simmons DL, Cheung AK, Zhang Y, Doumas M, Nord J, Sweeney ME, Taylor AA, Herring C, Kostis WJ, Powell J, Rastogi A, Roumie CL, Wiggers A, Williams JS, Yunis R, Zias A, Evans GW, Greene T, Rocco MV, Cushman WC, Reboussin DM, Feinglos MN, Papademetriou V, SPRINT Research Group. (date unknown). Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Accepted, .
  • Beddhu S, Baird B, Ma X, Cheung AK, Greene T (date unknown). Serum alkaline phosphatase and mortality in hemodialysis patients. Vol. 74, 91-6. Accepted, .
  • Goldfarb-Rumyantzev AS, Baird BC, Leypoldt JK, Cheung AK (date unknown). The association between BP and mortality in patients on chronic peritoneal dialysis. Vol. 20, 1693-701. Accepted, .
  • Steuer RR, Germain MJ, Leypoldt JK, Cheung AK (date unknown). Enhanced fluid removal guided by blood volume monitoring during chronic hemodialysis. Vol. 22, 627-32. Accepted, .
  • Leypoldt JK, Cheung AK, Deeter RB (date unknown). Effect of hemodialyzer reuse: dissociation between clearances of small and large solutes. Vol. 32, 295-301. Accepted, .
  • Leypoldt JK, Cheung AK, Steuer RR, Harris DH, Conis JM (date unknown). Determination of circulating blood volume by continuously monitoring hematocrit during hemodialysis. Vol. 6, 214-9. Accepted, .
  • Cheung AK, Wu LL, Kablitz C, Leypoldt JK (date unknown). Atherogenic lipids and lipoproteins in hemodialysis patients. Vol. 22, 271-6. Accepted, .
  • Munger MA, Gardner SF, Ateshkadi A, Rabetoy GM, Barri YM, Stoddard GJ, Cheung AK (date unknown). Misoprostol effects on diclofenac-induced cardiorenal changes in salt-sensitive patients with hypertension: the MEDIC Study. Vol. 28, 834-42. Accepted, .
  • Ramkumar N, Beddhu S, Eggers P, Pappas LM, Cheung AK (date unknown). Patient preferences for in-center intense hemodialysis. Vol. 9, 281-95. Accepted, .
  • Rocco MV, Yan G, Heyka RJ, Benz R, Cheung AK (date unknown). Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Vol. 21, 280-8. Accepted, .
  • Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS (date unknown). Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Vol. 58, 353-62. Accepted, .
  • Munger MA, Ateshkadi A, Cheung AK, Flaharty KK, Stoddard GJ, Marshall EH (date unknown). Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffers. Vol. 36, 130-9. Accepted, .
  • Kozek-Langenecker SA, Masaki T, Mohammad H, Green W, Mohammad SF, Cheung AK (date unknown). Fibrinogen fragments and platelet dysfunction in uremia. Vol. 56, 299-305. Accepted, .
  • Cheung AK, Faezi-Jenkin B, Leypoldt JK (date unknown). Effect of thrombosis on complement activation and neutrophil degranulation during in vitro hemodialysis. Vol. 5, 110-5. Accepted, .
  • Steuer RR, Leypoldt JK, Cheung AK, Harris DH, Conis JM (date unknown). Hematocrit as an indicator of blood volume and a predictor of intradialytic morbid events. Vol. 40, M691-6. Accepted, .
  • Butler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C (date unknown). Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. Vol. 12, e005875. Accepted, .
  • Kuji T, Masaki T, Goteti K, Li L, Zhuplatov S, Terry CM, Zhu W, Leypoldt JK, Rathi R, Blumenthal DK, Kern SE, Cheung AK (date unknown). Efficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosis. Vol. 69, 2179-85. Accepted, .
  • Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS (date unknown). Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Vol. 65, 2380-9. Accepted, .
  • Leypoldt JK, Cheung AK, Agodoa LY, Daugirdas JT, Greene T, Keshaviah PR (date unknown). Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. The Hemodialysis (HEMO) Study. Vol. 51, 2013-7. Accepted, .
  • Morton KA, Pisani DE, Whiting JH Jr, Cheung AK, Arias JM, Valdivia S (date unknown). Determination of glomerular filtration rate using technetium-99m-DTPA with differing degrees of renal function. Vol. 25, 110-4. Accepted, .
  • Cheung AK, DeVault GA Jr, Gregory MC (date unknown). A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. Vol. 3, 1884-91. Accepted, .
  • Zhu W, Masaki T, Cheung AK, Kern SE (date unknown). In-vitro Release of Rapamycin from a Thermosensitive Polymer for the Inhibition of Vascular Smooth Muscle Cell Proliferation. Vol. 1, 3-12. Accepted, .
  • Goldfarb-Rumyantzev AS, Hurdle JF, Baird BC, Stoddard G, Wang Z, Scandling JD, Barenbaum LL, Cheung AK (date unknown). The role of pre-emptive re-transplant in graft and recipient outcome. Vol. 21, 1355-64. Accepted, .
  • Masaki T, Gilson J, Leypoldt JK, Cheung AK (date unknown). Effect of permeability on indices of haemodialysis membrane biocompatibility. Vol. 14, 1176-81. Accepted, .
  • Cheung AK, Leypoldt JK (date unknown). The hemodialysis membranes: a historical perspective, current state and future prospect. Vol. 17, 196-213. Accepted, .
  • Cheung AK, Parker CJ, Ren K, Iverius PH (date unknown). Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma. Vol. 49, 1360-71. Accepted, .
  • Huang CX, Tighiouart H, Beddhu S, Cheung AK, Dwyer JT, Eknoyan G, Beck GJ, Levey AS, Sarnak MJ (date unknown). Both low muscle mass and low fat are associated with higher all-cause mortality in hemodialysis patients. Vol. 77, 624-9. Accepted, .
  • Goteti K, Masaki T, Kuji T, Leypoldt JK, Cheung AK, Kern SE (date unknown). Perivascular tissue pharmacokinetics of dipyridamole. Vol. 23, 718-28. Accepted, .
  • Zhu W, Masaki T, Bae YH, Rathi R, Cheung AK, Kern SE (date unknown). Development of a sustained-release system for perivascular delivery of dipyridamole. Vol. 77, 135-43. Accepted, .
  • Beddhu S, Samore MH, Roberts MS, Stoddard GJ, Pappas LM, Cheung AK (date unknown). Creatinine production, nutrition, and glomerular filtration rate estimation. Vol. 14, 1000-5. Accepted, .
  • Kozek-Langenecker SA, Mohammad SF, Masaki T, Kamerath C, Cheung AK (date unknown). The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry. Vol. 90, 808-12. Accepted, .
  • Luo Q, Cheung AK, Kamerath CD, Reimer LG, Leypoldt JK (date unknown). Increased protein loss during peritonitis associated with peritoneal dialysis is neutrophil dependent. Vol. 57, 1736-42. Accepted, .
  • Steuer RR, Leypoldt JK, Cheung AK, Senekjian HO, Conis JM (date unknown). Reducing symptoms during hemodialysis by continuously monitoring the hematocrit. Vol. 27, 525-32. Accepted, .
  • Preston JS, Tasdizen T, Terry CM, Cheung AK, Kirby RM (date unknown). Using the stochastic collocation method for the uncertainty quantification of drug concentration due to depot shape variability. Vol. 56, 609-20. Accepted, .
  • Ramkumar N, Murtaugh MA, Cheung AK, Beddhu S (date unknown). Lack of synergistic effects of metabolic syndrome and plasma fibrinogen on coronary events and mortality in moderate CKD. Vol. 49, 356-64. Accepted, .
  • Chelamcharla M, Leypoldt JK, Cheung AK (date unknown). Dialyzer membranes as determinants of the adequacy of dialysis. Vol. 25, 81-9. Accepted, .
  • Cheung AK, Parker CJ, Hohnholt M (date unknown). Beta2 integrins are required for neutrophil degranulation induced by hemodialysis membranes. Vol. 43, 649-60. Accepted, .
  • Chang TI, Friedman GD, Cheung AK, Greene T, Desai M, Chertow GM (date unknown). Systolic blood pressure and mortality in prevalent haemodialysis patients in the HEMO study. Vol. 25, 98-105. Accepted, .
  • Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G (date unknown). Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. Vol. 17, 546-55. Accepted, .
  • Kwan BC, Beddhu S, Kronenberg F, Cheung AK (date unknown). Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis?. Vol. 2, 76-7. Accepted, .
  • Rocco MV, Cheung AK, Greene T, Eknoyan G (date unknown). The HEMO Study: applicability and generalizability. Vol. 20, 278-84. Accepted, .
  • Leypoldt JK, Cheung AK (date unknown). Removal of high-molecular-weight solutes during high-efficiency and high-flux haemodialysis. Vol. 11, 329-35. Accepted, .
  • Allon M, Litovsky SH, Tey JCS, Sundberg CA, Zhang Y, Chen Z, Fang Y, Cheung AK, Shiu YT (date unknown). Abnormalities of vascular histology and collagen fiber configuration in patients with advanced chronic kidney disease. Vol. 20, 31-40. Accepted, .
  • Palit S, Chonchol M, Cheung AK, Kaufman J, Smits G, Kendrick J (date unknown). Association of BP with death, cardiovascular events, and progression to chronic dialysis in patients with advanced kidney disease. (PMID: 25979975). 934-940. Accepted, .
  • Yan G, Cheung AK, Greene T, Yu AJ, Oliver MN, Yu W, Ma JZ, Norris KC (date unknown). Interstate variation in receipt of nephrologist care in US patients approaching ESRD: race, age, and state characteristics. Clin J Am Soc Nephrol 10:1979-1988, 2015 (PMID: 26450930). Accepted, .
  • Kuttykrishnan S, Kalantar-Zadeh K, Arah OA, Cheung AK, Brunelli S, Heagerty PJ, Katz R, Molnar MZ, Nissenson A, Ravel V, Streja E, Himmelfarb J, Mehrotra R (date unknown). Predictors of treatment with dialysis modalities in observational studies for comparative effectiveness research. (PMID: 25883196). 1208-1217. Accepted, .
  • Terry CM, Zhuplatov I, He Y, Wun TC, Kim SE, Cheung AK: (date unknown). Assessment of novel anti-thrombotic fusion proteins for inhibition of stenosis in a porcine model of arteriovenous graft. (PMID: 26360605). Accepted, .
  • Jovanovich AJ, Chonchol MB, Sobhi A, Kendrick JB, Cheung AK, Kaufman JS, Smits G, Jablonski KL and the HOST Investigators: (date unknown). Mineral metabolites, angiotensin II inhibition, and outcomes in advanced chronic kidney disease. in press. Accepted, .
  • Zhou G, Liu X, Cheung AK, Huang Y (date unknown). Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus? (PMID: 26175845). 825-840. Accepted, .
  • Mehrotra R, Soohoo M, Rivara M, Himmelfarb J, Cheung AK, Arah OA, Nissenson A, Ravel V, Streja E, Kuttykrishnan S, Katz R, Molnar MZ, Kalantar-Zadeh K (date unknown). Racial and ethnic disparities in utilization of and outcomes with home dialysis in the United States. 2123-2134. Accepted, .
  • Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Mahboob Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT, for the SPRINT Study Research Group: (date unknown). A randomized trial of intensive versus standard blood pressure control. Accepted, .
  • Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK (date unknown). Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO Study. (Epub ahead of print ). (PMID: 2597143. Accepted, .
  • Yan G, Norris KC, Greene T, Yu AJ, Ma JZ, Yu W, Cheung AK (date unknown). Race/ethnicity, age, and risk of hospital admission and length of stay during the first year of maintenance hemodialysis, (PMID: 24948142). 1402-1409. Accepted, .
  • Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr, Whelton PK, The SPRINT Study Research Group: (date unknown). The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). (PMID: 24902920). 532-546. Accepted, .
  • Guo X, Zhou G, Guo M, Cheung AK, Huang Y, Beddhu S (date unknown). Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II, (PMID: 24744899). 2e00230. Accepted, .
  • Zhang JL, Morrell G, Rusinek H, Warner L, Vivier PH, Cheung AK, Lerman LO, Lee VS (date unknown). Measurement of renal tissue oxygenation with blood oxygen level-dependent MRI and oxygen transit modeling. (PMID: 24452640). F579-587. Accepted, .
  • Dember LM, Imrey PB, Beck GJ, Cheung AK, Himmelfarb J, Huber TS, Kusek JW, Roy-Chaudhury P, Vazquez MA, Alpers CE, Robbin ML, Vita JA, Greene T, Gassman JJ, Feldman HI, (date unknown). Hemodialysis Fistula Maturation Study Group: Objectives and design of the Hemodialysis Fistula Maturation Study. (PMID: 23992885). 104-112. Accepted, .
  • Zhang J, Gu C, Lawrence DA, Cheung AK, Huang Y (date unknown). A plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytes. (PMID: 24443353). 802-815. Accepted, .
  • Terry CM, Carlson ML, He Y, Ulu A, Morisseau C, Blumenthal DK, Hammock BD, Cheung AK: (date unknown). Aberrant soluble epoxide hydrolase and oxylipin levels in a porcine arteriovenous graft stenosis model, (PMID: 25196102). 269-282. Accepted, .
  • Chang, TI, Flythe JE, Brunelli SM, Muntner P, Greene T, Cheung AK, Chertow GM (date unknown). Visit-to-visit systolic blood pressure variability and outcomes in hemodialysis. (PMID: 23803593). Vol. 28, 18-24. Accepted, .
  • Jovanovich AJ, Chonchol M, Brady CB, Kaufman JD, Kendrick J, Cheung AK, Jablonski KL (date unknown). 25-Vitamin D, 1,25-vitamin D, parathyroid hormone, fibroblast growth factor-23 and cognitive function in men with advanced CKD: A veteran population, (PMID: 25208315). 296-303. Accepted, .
  • Zhou G, Cheung AK, Liu X, Huang Y (date unknown). Valsartan slows the progression of diabetic nephropathy in db/db mice via reduction in podocyte injury and renal oxidative stress and inflammation.(PMID: 24195695). 707-720. Accepted, .
  • Yan G, Cheung AK, Ma JZ, Yu AJ, Greene T, Oliver MN, Yu W, Norris KC (date unknown). The associations between race and geographic area and quality-of-care indicators in patients approaching ESRD. (PMID: 23493380). 610-618. Accepted, .
  • Raphael KL, Zhang Y, Wei G, Greene T, Cheung AK, Beddhu S, El Nahas M (date unknown). Serum bicarbonate and mortality in adults in NHANES III. (PMID: 23348878). 1207-12. Accepted, .
  • . Yan G, Norris KC, Yu AJ, Ma JZ, Greene T, Yu W, Cheung AK: (date unknown). The relationship of age, race and ethnicity with survival in dialysis patients. (PMID: 23539227). 953-961. Accepted, .
  • Sharma S, Joseph J, Chonchol M, Kaufman JS, Cheung AK, Rafeq Z, Smits G, Kendrick J (date unknown). Higher fibroblast growth factor-23 concentrations associate with left ventricular systolic dysfunction in dialysis patients. (PMID: 23849306). 313-321. Accepted, .
  • Yan G, Norris KC, Xin W, Ma JZ, Yu AJ, Greene T, Yu W, Cheung AK: (date unknown). Facility size, race and ethnicity, and mortality for in-center hemodialysis. (PMID: 23970120). 2062-2070. Accepted, .
  • Filipowicz R, Greene T, Wei G, Cheung AK, Raphael KL, Baird BC, Beddhu S (date unknown). Associations of serum skeletal alkaline phosphatase with elevated C-reactive protein and mortality. Vol. 8, 26-32. Accepted, .
  • 141. Montford JR, Chonchol M, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Kendrick J: (date unknown). Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23. Accepted, .
  • Sanders WG, Morisseau C, Hammock BD, Cheung AK, Terry CM (date unknown). Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-Inflammatory effects of a soluble epoxide hydrolase inhibitor. Accepted, .
  • Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, HOST Study Investigators (date unknown). Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease. Vol. Epub ahead, of print. Accepted, .
  • Brinton, MR, Tagge CA, Stewart RJ, Cheung AK, Shiu YT, Christensen DA (date unknown). Thermal sensitivity of endothelial cells on synthetic vascular graft material. Vol. 28, 163-174. Accepted, .
  • Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol MB, and the HOST Investigators (date unknown). : A biodegradable perivascular wrap for controlled, local and directed drug delivery. Accepted, .
  • Shastri S, Tangri N, Tighiouart H, Beck GJ, Vlagopoulos P, Ornt D, Eknoyan G, Kusek JW, Herzog C, Cheung AK, Sarnak MJ (date unknown). Risk factors and a prediction model for sudden cardiac in the HEMO Study. Vol. 7, 123-130. Accepted, .
  • Jovanovich A, Chonchol M, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Kendrick J, and the HOST Investigators (date unknown). Racial differences in markers of mineral metabolism in advanced chronic kidney disease. Vol. 7, 640-647. Accepted, .
  • Sanders WG, Hogrebe PC, Grainger DW, Cheung AK, Terry CM (date unknown). A biodegradable perivascular wrap for controlled, local and directed drug delivery. Vol. 161, 81-89. Accepted, .
  • Terry CM, Li L, Li H, Zhuplatov I, Blumenthal DK, Kim S-E, Owen SC, Kholmovski EG, Fowers KD, Rathi R, Cheung AK (date unknown). In vivo evaluation of the delivery and efficacy of a sirolimus-laden polymer gel for inhibition of hyperplasia in a porcine model of arteriovenous hemodialysis graft stenosis. Vol. 160, 459-467. Accepted, .
  • Brinton MR, Stewart RJ, Cheung AK, Christensen DA, Shiu Y-T E (date unknown). Modelling ultrasound-induced mild hyperthermia of hyperplasia in vascular grafts. Vol. 8, 42. Accepted, .
  • Agar BU, Akonu RA, Lo Y-C, Cheung AK, Leypoldt JK (date unknown). Kinetic model of phosphorus mobilization during and after short and conventional hemodialysis. Vol. 6, 2854-2860. Accepted, .
  • Agar BU, Akonur A, Cheung AK, Leypoldt JK (date unknown). A simple method to estimate phosphorus mobilization in hemodialysis using only predialytic and postdialytic blood samples. Vol. 15, S9-S14. Accepted, .
  • Chang, TI, Paik, J, Greene T, Desai M, Bech F, Cheung AK, Chertow GM (date unknown). Intradialytic hypotension and vascular access thrombosis. Vol. 22, 1526-1533. Accepted, .
  • Chang TI, Shilane D, Brunelli SM, Cheung AK, Chertow GM, Winkelmayer WC (date unknown). Angiotensin-converting enzyme inhibitors and cardiovascular outcomes in patients on maintenance hemodialysis. Vol. 162, 324-330. Accepted, .
  • Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, HOST Investigators (date unknown). FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. Vol. 22, 1913-1922. Accepted, .
  • Tangri N, Shastri S, Tighiouart H, Beck GJ, Cheung AK, Eknoyan G, Sarnak MJ (date unknown). Beta-blockers for prevention of sudden cardiac death in patients on hemodialysis: A propensity score analysis of the HEMO Study. Vol. 58, 939-945. Accepted, .
  • Kopple JD, Cheung AK, Christiansen JS, Djurhuus CB, Nahas ME, Feldt-Rasmussen B, Mitch WE, Wanner C, Göthberg M, T. Ikizler TA (date unknown). OPPORTUNITYTM: A large-scale randomized clinical trial of growth hormone in hemodialysis patients. Vol. 26, 4095-4103. Accepted, .
  • Li L, Blumenthal DK, Terry CM, He Y, Carlson ML, Cheung AK (date unknown). PDGF-induced proliferation in human arterial and venous smooth muscle cells: molecular basis for differential effects of PDGF isoforms. Vol. 112, 289-298. Accepted, .
  • Wali RK, Iyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, Henrich WL, Cheung AK (date unknown). Efficacy and safety of carvedilol in treatment of heart failure in chronic kidney disease: A meta-analysis of randomized trials. Vol. 4, 18-26. Accepted, .
  • Damera S, Raphael KL, Baird BC, Cheung AK, Greene T, Beddhu S (date unknown). Serum alkaline phosphatase levels associate with elevated serum C-reactive protein in chronic kidney disease. Vol. 79, 228-33. Accepted, .
  • Terry CM, Kim SE, Li L, Goodrich KC, Hadley JR, Blumenthal DK, Parker DL, Cheung AK (date unknown). Longitudinal assessment of hyperplasia using magnetic resonance imaging without contrast in a porcine arteriovenous graft model. Vol. 16, 96-107. Accepted, .
  • Goldfarb-Rumyantzev AS, Chelamcharla M, Bray BE, Leypoldt JK, Lavasani I, Nelson N, Lavasani T, Baird B, Cheung AK (date unknown). Volume indicators and left ventricular mass during aggressive volume management in patients on thrice-weekly hemodialysis. Vol. 113, c270-80. Accepted, .
  • Naiman N, Cheung AK, Goldfarb-Rumyantzev AS (date unknown). Familiality of cardiovascular mortality in end-stage renal disease patients. Vol. 29, 237-43. Accepted, .
  • Cheung AK, Terry C, Li L (date unknown). Pathogenesis and local drug delivery for prevention of vascular access stenosis. Vol. 18, 140-5. Accepted, .
  • Cheung AK, Greene T, Leypoldt JK, Yan G, Allon M, Delmez J, Levey AS, Levin NW, Rocco MV, Schulman G, Eknoyan G (date unknown). Association between serum 2-microglobulin level and infectious mortality in hemodialysis patients. Vol. 3, 69-77. Accepted, .
  • Chonchol M, Goldenberg I, Moss AJ, McNitt S, Cheung AK (date unknown). Risk factors for sudden cardiac death in patients with chronic renal insufficiency and left ventricular dysfunction. Vol. 27, 7-14. Accepted, .
  • Goldfarb-Rumyantzev AS, Leypoldt JK, Nelson N, Kutner NG, Cheung AK (date unknown). A crossover study of short daily haemodialysis. Vol. 21, 166-75. Accepted, .
  • Delmez JA, Yan G, Bailey J, Beck GJ, Beddhu S, Cheung AK, Kaysen GA, Levey AS, Sarnak MJ, Schwab SJ (date unknown). Cerebrovascular disease in maintenance hemodialysis patients: results of the HEMO Study. Vol. 47, 131-8. Accepted, .
  • Goldfarb-Rumyantzev AS, Cheung AK, Habib AN, Wang BJ, Lin SJ, Baird BC, Naiman N, Cannon-Albright L (date unknown). A population-based assessment of the familial component of chronic kidney disease mortality. Vol. 26, 142-8. Accepted, .
  • Kim S-J, Masaki T, Rowley R, Leypoldt JK, Mohammad SF, Cheung AK (date unknown). Different responses by cultured aortic and venous smooth muscle cells to radiation. Vol. 68, 371-377. Accepted, .
  • Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, Wang Z, Baird B, Barenbaum L, Cheung AK (date unknown). Duration of end-stage renal disease and kidney transplant outcome. Vol. 20, 167-75. Accepted, .
  • Masaki T, Kamerath CD, Kim SJ, Leypoldt JK, Mohammad SF, Cheung AK (date unknown). In vitro pharmacological inhibition of human vascular smooth muscle cell proliferation for the prevention of hemodialysis vascular access stenosis. Vol. 22, 307-12. Accepted, .
  • Depner TA, Greene T, Daugirdas JT, Cheung AK, Gotch FA, Leypoldt JK (date unknown). Dialyzer performance in the HEMO Study: in vivo K0A and true blood flow determined from a model of cross-dialyzer urea extraction. Vol. 50, 85-93. Accepted, .
  • Leypoldt JK, Cheung AK, Chirananthavat T, Gilson JF, Kamerath CD, Deeter RB (date unknown). Hollow fiber shape alters solute clearances in high flux hemodialyzers. Vol. 49, 81-7. Accepted, .
  • 68. Zebrack JS, Anderson JL, Beddhu S, Horne BD, Bair TL, Cheung A, Muhlestein JB for the Intermountain Heart Collaborative Study Group (date unknown). Do Associations with C-reactive protein and extent of coronary artery disease account for the increased cardiovascular risk of renal insufficiency?. Vol. 42, 57-63. Accepted, .
  • Bergstrom J, Lysaght M, Cheung AK (date unknown). The career of Lee W. Henderson. Vol. 13 Suppl 1, S1-2. Accepted, .
  • Leypoldt JK, Cheung AK (date unknown). Optimal use of hemodialyzers. 129-37. Accepted, .
  • Leypoldt JK, Cheung AK, Delmez JA, Gassman JJ, Levin NW, Lewis JA, Lewis JL, Rocco MV (date unknown). Relationship between volume status and blood pressure during chronic hemodialysis. Vol. 61, 266-75. Accepted, .
  • Peng H, Cheung AK, Reimer LG, Kamerath CD, Leypoldt JK (date unknown). Effect of indomethacin on peritoneal protein loss in a rabbit model of peritonitis. Vol. 59, 44-51. Accepted, .
  • Kozek-Langenecker SA, Mohammad SF, Masaki T, Green W, Kamerath C, Cheung AK (date unknown). The effects of aprotonin on platelets in vitro using whole blood flow cytometry. Vol. 90, 12-6. Accepted, .
  • Leypoldt JK, Cheung AK, Carroll CE, Stannard DC, Pereira BJG, Agodoa LY, Port FK (date unknown). Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Vol. 33, 349-355. Accepted, .
  • Leypoldt JK, Cheung AK (date unknown). The effect of low dialysate flow rate on hemodialyzer mass transfer-area coefficients of urea and creatinine. Vol. 3, 51-54. Accepted, .
  • Cheung AK, Agodoa LY, Clark W, Daugirdas, JT, Depner TA, Gotch FA, Greene T, Levin NW, Leypoldt JK, and the Hemodialysis (HEMO) Study (date unknown). Effects of hemodialyzer reuse on clearances of urea and ß2-microglobulin. Vol. 10, 117-127. Accepted, .
  • Ing TS, Cheung AK, Golper TA, Lang GR, Lazarus JM, Letteri JM, Levin NW, Lundin AP, Molony DA, Mujais SK, Port FK, Ward RA (date unknown). National Kidney Foundation report on dialyzer reuse. Vol. 30, 859-871. Accepted, .
  • Leypoldt JK, Gilson JF, Blindauer KM, Cheung AK (date unknown). Macromolecule adsorption to hemodialysis membranes depends on molecular size. Vol. 10, 53-60. Accepted, .
  • Levin NW, Kotanko P, Eckardt KU, Kasiske BL, Chazot C, Cheung AK, Redon J, Wheeler DC, Zoccali C, London GM (date unknown). Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. (pp. 273-84). Vol. 77. Accepted, .
  • Cheung AK, Ward RA (date unknown). ASN Renal Weekends slide set, American Society of Nephrology. American Society of Nephrology. Accepted, .
  • Cheung AK (date unknown). Is lipid control necessary in hemodialysis patients?. (pp. S95-101). Vol. 4 Suppl 1. Accepted, .
  • Li L, Terry CM, Shiu YT, Cheung AK (date unknown). Neointimal hyperplasia associated with synthetic hemodialysis grafts. (pp. 1247-61). Vol. 74. Accepted, .
  • Charney DI, Walton DF, Cheung AK (date unknown). Atherosclerosis in chronic renal failure. (pp. 876-82). Vol. 2. Accepted, .
  • Nissenson AR, Agarwal R, Allon M, Cheung AK, Clark W, Depner T, Diaz-Buxo JA, Kjellstrand C, Kliger A, Martin KJ, Norris K, Ward R, Wish J (date unknown). Improving outcomes in CKD and ESRD patients: carrying the torch from training to practice. (pp. 380-97). Vol. 17. Accepted, .
  • Henderson LW, Clark WR, Cheung AK (date unknown). Quantification of middle molecular weight solute removal in dialysis. (pp. 294-9). Vol. 14. Accepted, .
  • Leypoldt JK, Cheung AK (date unknown). Characterization of molecular transport in artificial kidneys. (pp. 381-9). Vol. 20. Accepted, .
  • Kwan BC, Kronenberg F, Beddhu S, Cheung AK (date unknown). Lipoprotein metabolism and lipid management in chronic kidney disease. (pp. 1246-61). Vol. 18. Accepted, .
  • Roy-Chaudhury P, Sukhatme VP, Cheung AK (date unknown). Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. (pp. 1112-27). Vol. 17. Accepted, .
  • Leypoldt JK, Cheung AK (date unknown). Revisiting the hemodialysis dose. (pp. 96-101). Vol. 19. Accepted, .
  • Isakova T, Ix JH, Sprague SM, Raphael KL Fried L, Gassman JJ, Raj D, Cheung AK, Kusek JW, Flessner MF, Wolf M, Block GA (date unknown). Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD (PMID: 25967123). (pp. 2328-2339). Vol. 26. Accepted, .
  • Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J: (date unknown). GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration, 64:821-835 (PMID: 25441437). Accepted, .
  • Zhang JL, Morrell G, Rusinek H, Sigmund EE, Chandarana H, Lerman LO, Prasad PV, Niles D, Artz N, Fain S, Vivier PH, Cheung AK, Lee VS: (date unknown). New magnetic resonance imaging methods in nephrology (PMID: 24067433). (pp. 768-778). Vol. 85. Accepted, .
  • Molitoris BA, Okusa MD, Palevsky PM, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Faubel SG, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA: (date unknown). Design of clinical trials in AKI: A Report from an NIDDK Workshop. Trials of patients with sepsis and in selected hospital settings (PMID: 22442184). (pp. 856-860). Vol. 7. Accepted, .
  • Palevsky PM, Molitoris BA, Okusa MD, Levin A, Waikar SS, Wald R, Chertow GM, Murray PT, Parikh CR, Shaw AD, Go AS, Faubel SG, Kellum JA, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene T, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA (date unknown). Design of clinical trials in acute kidney injury: Report from an NIDDK Workshop on trial methodology. (pp. of print). Vol. Epub ahead. Accepted, .
  • Molitoris BA, Okusa MD, Palevsky PM, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Faubel SG, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA (date unknown). Design of clinical trials in AKI: A Report from an NIDDK Workshop. Trials of patients with sepsis and in selected hospital settings. (pp. of print). Vol. Epub ahead. Accepted, .
  • Okusa MD, Molitoris BA, Palevsky PM, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Faubel S, Kellum JA, Wald R, Chertow GM, Levin A, Waikar SS, Murray PT, Parikh CR, Shaw AD, Go AS, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene TH, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA (date unknown). Design of clinical trials in acute kidney injury: A report from an NIDDK Workshop – prevention trials. (pp. of print). Vol. Epub ahead. Accepted, .
  • Palevsky PM, Molitoris BA, Okusa MD, Levin A, Waikar SS, Wald R, Chertow GM, Murray PT, Parikh CR, Shaw AD, Go AS, Faubel SG, Kellum JA, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene T, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA: (date unknown). Design of clinical trials in acute kidney injury: Report from an NIDDK Workshop on trial methodology. 7:844-850, (PMID: 22442182). Accepted, .
  • Raphael KL, Cheung AK (date unknown). Implications of the Frequent Hemodialysis Network-Daily Trial. (pp. 621-628). Vol. 24. Accepted, .
  • Redon J, Martinez F, Cheung AK (date unknown). Special considerations for antihypertensive agents in dialysis patients. (pp. 93-8). Vol. 29. Accepted, .
  • Cheung AK (date unknown). Contributing author on several topics. Accepted, .
  • Leypoldt JK, Cheung AK (date unknown). Extracellular volume in nocturnal hemodialysis. (pp. S50-S54). Vol. 12. Accepted, .
  • Leypoldt JK, Cheung AK (date unknown). Evaluating volume status in hemodialysis patients. (pp. 64-74). Vol. 5. Accepted, .
  • Cheung AK, Leypoldt JK (date unknown). Evaluation of hemodialyzer performance. (pp. 131-137). Vol. 11. Accepted, .
  • Cheung AK (date unknown). Stages of future technological developments in haemodialysis. (pp. 52-8). Vol. 11 Suppl 8. Accepted, .
  • Charney DI, Walton DF, Cheung AK (date unknown). Difficult management problems in dialysis: Impotence II. (pp. 22-29). Vol. 7. Accepted, .
  • Cheung AK (date unknown). Complement activation as index of haemodialysis membrane biocompatibility: the choice of methods and assays. (pp. 96-103). Vol. 9 Suppl 2. Accepted, .
  • Cheung AK, Lemke H (date unknown). Criteria and standardization for biocompatibility. (pp. 72-6). Vol. 9 Suppl 2. Accepted, .
  • Cheung AK (date unknown). Quantitation of dialysis. The importance of membrane and middle molecules. (pp. 42-53). Vol. 12. Accepted, .
  • Cheung AK (date unknown). Interactions between plasma proteins and hemodialysis membranes. (pp. 417-37). Vol. 22. Accepted, .
  • Cheung AK (date unknown). Clinical phenomena induced by complement and leukocyte interactions with artificial surfaces. (pp. 147-8). Vol. 7. Accepted, .